Literature DB >> 33800138

New-Onset Diabetes after Kidney Transplantation.

Claudio Ponticelli1, Evaldo Favi2,3, Mariano Ferraresso2,3.   

Abstract

New-onset diabetes mellitus after transplantation (NODAT) is a frequent complication in kidney allograft recipients. It may be caused by modifiable and non-modifiable factors. The non-modifiable factors are the same that may lead to the development of type 2 diabetes in the general population, whilst the modifiable factors include peri-operative stress, hepatitis C or cytomegalovirus infection, vitamin D deficiency, hypomagnesemia, and immunosuppressive medications such as glucocorticoids, calcineurin inhibitors (tacrolimus more than cyclosporine), and mTOR inhibitors. The most worrying complication of NODAT are major adverse cardiovascular events which represent a leading cause of morbidity and mortality in transplanted patients. However, NODAT may also result in progressive diabetic kidney disease and is frequently associated with microvascular complications, eventually determining blindness or amputation. Preventive measures for NODAT include a careful assessment of glucose tolerance before transplantation, loss of over-weight, lifestyle modification, reduced caloric intake, and physical exercise. Concomitant measures include aggressive control of systemic blood pressure and lipids levels to reduce the risk of cardiovascular events. Hypomagnesemia and low levels of vitamin D should be corrected. Immunosuppressive strategies limiting the use of diabetogenic drugs are encouraged. Many hypoglycemic drugs are available and may be used in combination with metformin in difficult cases. In patients requiring insulin treatment, the dose and type of insulin should be decided on an individual basis as insulin requirements depend on the patient's diet, amount of exercise, and renal function.

Entities:  

Keywords:  NODAT; calcineurin inhibitor; cardiovascular disease; diabetes; immunosuppression; kidney transplantation; mTOR inhibitor; new-onset diabetes after transplantation; renal allograft; steroid

Year:  2021        PMID: 33800138      PMCID: PMC7998982          DOI: 10.3390/medicina57030250

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  86 in total

Review 1.  mTOR and Cardiovascular Diseases: Diabetes Mellitus.

Authors:  Bruno Vergès
Journal:  Transplantation       Date:  2018-02       Impact factor: 4.939

2.  Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus.

Authors:  Ana Elena Rodriguez-Rodriguez; Javier Donate-Correa; Jordi Rovira; Germán Cuesto; Diego Luis-Ravelo; Miguel X Fernandes; Abraham Acevedo-Arozena; Fritz Diekmann; Angel Acebes; Armando Torres; Esteban Porrini
Journal:  Am J Transplant       Date:  2019-07-08       Impact factor: 8.086

3.  Post-transplant diabetes mellitus in renal allograft recipients: a matched-pair control study.

Authors:  A von Kiparski; D Frei; G Uhlschmid; F Largiadèr; U Binswanger
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

Review 4.  Prevention and management of transplant-associated diabetes.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Expert Opin Pharmacother       Date:  2011-11-03       Impact factor: 3.889

Review 5.  Do sulphonylureas still have a place in clinical practice?

Authors:  Kamlesh Khunti; Sudesna Chatterjee; Hertzel C Gerstein; Sophia Zoungas; Melanie J Davies
Journal:  Lancet Diabetes Endocrinol       Date:  2018-02-28       Impact factor: 32.069

6.  Causes of late transplant failure in cyclosporine-treated kidney allograft recipients.

Authors:  Gabriella Moroni; Valentina Binda; Silvana Quaglini; Lucia Sacchi; Francesca Raffiotta; Francesco Cosa; Giuseppe Montagnino; Evaldo Favi; Piergiorgio Messa; Claudio Ponticelli
Journal:  Clin Exp Nephrol       Date:  2019-04-23       Impact factor: 2.801

7.  Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes.

Authors:  F G Cosio; L J Hickson; M D Griffin; M D Stegall; Y Kudva
Journal:  Am J Transplant       Date:  2008-03       Impact factor: 8.086

8.  Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms.

Authors:  Gretchen N de Graav; Marieke van der Zwan; Carla C Baan; Joop A M J L Janssen; Dennis A Hesselink
Journal:  Transplant Direct       Date:  2018-02-20

9.  The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.

Authors:  Kenichi Tanaka; Yosuke Okada; Hiroko Mori; Keiichi Torimoto; Tadashi Arao; Yoshiya Tanaka
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

10.  New-onset diabetes after kidney transplantation: Incidence and associated factors.

Authors:  Vânia Gomes; Florbela Ferreira; José Guerra; Maria João Bugalho
Journal:  World J Diabetes       Date:  2018-07-15
View more
  3 in total

1.  IL-37 overexpression promotes endometrial regenerative cell-mediated inhibition of cardiac allograft rejection.

Authors:  Hong Qin; Chenglu Sun; Yanglin Zhu; Yafei Qin; Shaohua Ren; Zhaobo Wang; Chuan Li; Xiang Li; Baoren Zhang; Jingpeng Hao; Guangming Li; Hongda Wang; Bo Shao; Jingyi Zhang; Hao Wang
Journal:  Stem Cell Res Ther       Date:  2022-07-15       Impact factor: 8.079

2.  Clinical and Surgical Challenges in Kidney Transplantation: Toward a Personalized Approach?

Authors:  Evaldo Favi; Roberto Cacciola
Journal:  Medicina (Kaunas)       Date:  2022-04-27       Impact factor: 2.948

3.  Modeling type 2 diabetes in rats by administering tacrolimus.

Authors:  J C Quintana-Pérez; F García-Dolores; A S Valdez-Guerrero; D Alemán-González-Duhart; M G Arellano-Mendoza; S Rojas Hernández; I M Olivares-Corichi; J R García Sánchez; J G Trujillo Ferrara; F Tamay-Cach
Journal:  Islets       Date:  2022-12-31       Impact factor: 2.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.